Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15752165 | 0.92 | L3MBTL3 (0.37) | L3MBTL3L3MBTL1TSHRHDAC2NPY2R | |
| Trifluoroacetic Acid SCHEMBL30122206 | 0.92 | TSHR (0.34) | L3MBTL3L3MBTL1TSHRHDAC2NPY2R | |
| Trifluoroacetic Acid SCHEMBL29877879 | 0.88 | CYP1A2 (0.35) | TSHRNPY2RCYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL25277778 | 0.87 | TSHR (0.30) | TSHR | |
| Trifluoroacetic Acid SCHEMBL347581 | 0.87 | CYP1A2 (0.41) | TSHRCYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL21712920 | 0.85 | — | — | |
| Trifluoroacetic Acid SCHEMBL5035153 | 0.85 | CYP1A2 (0.42) | TSHRCYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL30504395 | 0.83 | L3MBTL3 (0.35) | L3MBTL3L3MBTL1TSHRARG1 | |
| Trifluoroacetic Acid SCHEMBL31094826 | 0.81 | NPY2R (0.31) | L3MBTL3L3MBTL1NPY2RCYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL31439473 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812517-A | Antitumor compounds as UPR agonists and uses thereof | 南京圣和药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113292479-B | Preparation method of 5-azaspiro [2.4] heptane and salt thereof | 南京合巨药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-2738156-B1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS | KBP BIOSCIENCES USA INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9365499-B2 | 9-aminomethyl substituted tetracycline compounds | KBP BIOSCIENCES CO., LTD. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20140179638-A1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| EP-2738156-A1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND | KBP Biosciences Co., Ltd. (CN) | 2014-06-04 | — | — | EP | disclosed |
| EP-0541086-A1 | Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7 | Kaken Pharmaceutical Co., Ltd. (JP) | 1993-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179638-A1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, PRMT9 | L3MBTL3 264/4885L3MBTL1 938/4885TSHR 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.